Here’s a roundup of recent clinical trial and scientific study news:
Neoprobe Corp. (NYSE Amex:NEOP) reached an agreement to license an imaging technology patent from San Diego-based Naviscan Inc.
Dublin, Ohio-based Neoprobe will use Naviscan’s technology in conjunction with its own gamma-detection systems, which are used to evaluate the potential spread of cancer to lymph node tissues and organs, according to a prepared statement Naviscan.
Two studies show that gastric bypass surgery has better long-term results compared with sleeve gastrectomy and "lap-band" surgery.
The benefits of gastric bypass include greater weight loss, resolution of diabetes and improved quality of life, according to the two reports published in the February issue of Archives of Surgery.
Yesterday was a strange one on Wall Street for Neoprobe Corp. (NYSE:NEOP), as the company’s shares hit a 52-week but ended the day down about 3 percent.
In early trading Thursday, NEOP shares reached a 52-week high of $3.93, before falling throughout the rest of the day and closing at $3.73.
Neoprobe Corp. (OTC:NEOP) shares are slated to begin trading on the NYSE Amex this week.
The stock exchange’s officials cleared company’s common stock to be listed on the market beginning Feb. 10, according to the company.
Neoprobe shares are currently traded on the Over-the-Counter Bulletin Board (OTCBB) system. The company began the application process last August.
Neoprobe Corp. (OTC:NEOP) hired a biotechnology and pharmaceuticals industry veteran as its chief development officer.
Mark Pykett, 46, is stepping into the role, which calls for him to assist the company with its product and business development, partnering and investor relations efforts, according to a press release from the Dublin, Ohio-based firm.
Neoprobe Corp.‘s (OTC:NEOP) third quarter loss narrowed, but more importantly, the company remains on track to file for regulatory approval of its cancer-detecting drug Lymphoseek early next year.
Neoprobe Corp. (OTC:NEOP) shareholders took a bath in the second quarter, largely because of one-time charges related to converting their company’s debt to preferred equity.
Neoprobe Inc. (OTC:NEOP) has applied for listing on the New York Stock Exchange.
The move would make the Dublin, Ohio-based company more attractive to institutional investors and provide more liquidity for existing investors, according to a press release. CEO David Bupp said it could take “a number of weeks” before Neoprobe receives approval for the listing.